ACHE and Alzheimer disease: As predicted from the pharmacodynamics calculations and animal experiments (Figure 2 and Figure 3) [69,128], 8 weeks of oral MSF given three times per week to mild to moderate AD patients correctly produced an estimated ~66% CNS AChE inhibition [126], a level of CNS AChE inhibition that is at the upper end of the useful therapeutic window [87,88,89] and which resulted in strong cognitive improvement (~6 points on the ADAS-cog).